Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor Omomyc (OMO-103) with standard of care in metastatic pancreatic...
Results suggest that Omomyc MYC-targeted therapy could potentially open up a new treatment avenue for melanoma, and point to the future development of clinical trials to assess the efficacy of this mi...
Omomyc, a mini-therapeutic protein developed at the Vall d'Hebron Institute of Oncology (VHIO), has been shown in the preclinical phase in the laboratory to be able to enter cells and reach their nucl...
Después de demostrar su eficacia y buena tolerancia en modelos animales en el laboratorio, el tratamiento con Omomyc (OMO-103), un fármaco que inactiva a Myc, un gen clave para la proliferación ...
Peptomyc S.L., spin-off nacida del VHIO, ha producido Omomyc, la miniproteína inhibidora de Myc, y demostrado su actividad antitumoral tras administrarla por vía sanguínea por primera vez. El estud...